NCT07038915

STRIVE: A Single-arm Phase 2 Study on Treatment of Lung Squamous Cell Carcinoma by Tiragolumab Plus Ivonescimab for Patients Who Progressed on Platinum Doublets and Anti-PD-1/PD-L1

• Status: Withdrawn
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: M.D. Anderson Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To learn if the drug combination of tiragolumab and ivonescimab can help to control LSCC that got worse after standard treatment with platinum doublets and anti-PD-1/PD-L1 therapy.

Detailed description

Primary Objectives To determine the objective response rate (ORR) of metastatic LSCC patients who progressed on platinum doublets and anti-PD1/PD-L1 treated with Tiragolumab/Ivonescimab. Secondary Objectives To evaluate the investigator assessed progression-free survival (PFS) and overall survival (OS) based on Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 of tiragolumab in combination with ivonescimab To evaluate the duration of response (DoR) of tiragolumab in combination with ivonescimab, as assessed by investigator, based on RECIST v1.1 To evaluate the safety and tolerability of tiragolumab in combination with ivonescimab

Conditions

• Lung Squamous Cell Carcinoma
• Anti-PD1/PDL1 Antibody

Interventions

Type	Name	Description
DRUG	Tiragolumab	Given by IV
DRUG	Ivonescimab	Given by IV

Timeline

• Start date: 2025-07-28
• Primary completion: 2025-07-28
• Completion: 2025-07-28
• First posted: 2025-06-26
• Last updated: 2025-08-05

Regulatory

• FDA-regulated drug study